Study Finds Ozempic Works Well After 65

Adults over 65 taking semaglutide lost striking amounts of weight in a new analysis, adding fresh evidence that obesity drugs can deliver powerful results well past retirement age.

The study suggests the drug, sold as Ozempic and Wegovy, helped participants shed more than 15% of their body weight on average, far outpacing placebo treatment. Reports indicate many participants also moved out of obesity categories altogether and reached healthier weight ranges, a shift that carries consequences far beyond the scale.

The new analysis suggests semaglutide does more than trim weight in older adults — it may also improve the heart and metabolic risks that often rise with age.

That broader health picture may prove just as important as the weight loss itself. The summary says participants saw improvements in heart and metabolic health, reinforcing the idea that obesity treatment in older adults can target multiple risks at once. For a population that often faces higher rates of cardiovascular disease, diabetes, and reduced mobility, that combination could matter enormously.

The findings also push back against a long-running hesitation around aggressive weight treatment for older adults. Sources suggest clinicians have often weighed potential benefits against concerns about age, frailty, and complicated medical histories. This analysis does not settle every question, but it strengthens the case that age alone should not define who gets considered for effective obesity care.

What comes next will likely center on how these results shape treatment decisions in everyday medicine. Doctors, patients, and health systems will watch for more detail on safety, long-term outcomes, and which older adults benefit most. If the evidence continues to hold, semaglutide could become a more central tool in managing not just weight, but the wider health risks that follow obesity into older age.